Available Clinical Trials

Clinical Research is an integral part of oncology at Bon Secours Richmond Health System. Clinical trials give patients access to the newest and best treatments for cancer. Bon Secours Richmond Health System is proud to provide the same options as leading national cancer centers. Whether it is looking at new surgical or radiation interventions, or giving a brand new medication, We are striving to find better ways to treat, prevent, and manage cancer.

To inquire about participation in a clinical trial, please contact us at (804) 893-8717.

Please see the available, in-progress clinical trials at Bon Secours Richmond Health System. You may filter these results by searching by disease type or keyword.

Search Clinical Trials

Select Category       or   
Displaying All Clinical Trials (11 - 20 of 30)
ECOG-ACRIN EA1181

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

ECOG-ACRIN EA5191

A Randomized, Phase II Trial of Cabozatinib and Cabozaninib plus Nivolumab vs Standard Chemotherapy in Patients with previously treated NSCLC

ECOG-ACRIN EA8143

A Phase III Randomized Study Comparing Perioperative Nivolumab vs Observation in Treating Patients with Renal Cell Carcinoma Undergoing Nephrectomy

ECOG-ACRIN EAY131

NCI‐Molecular Analysis For Therapy Choice Program (NCI‐ MATCH)

FAQs

What are clinical trials, and why are they important? Are there different types of cancer clinical trials? Who manages clinical …

SWOG LUNG-MAP

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Merck MK3475-756

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for …

National Cancer Institute NCICOVID

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

NRG Oncology NRG-BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First Line HER2-Positive Metastatic Breast Cancer

NRG Oncology NRG-BR003

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin …